Rédaction Africa Links 24 with Damian Garde
Published on 2024-02-15 14:45:00
In today’s biotech update, we’ll take a look at Amylyx Pharmaceuticals’ pivotal study, the impact of macroeconomics on the biotech industry, the struggles faced by Aurinia Pharmaceuticals, and the potential rebound of pharmaceutical contractors. Let’s dive into each of these topics to understand what’s happening in the biotech world.
Amylyx Pharmaceuticals is anxiously awaiting the results of a pivotal study that will determine whether a rival ALS treatment can slow the progression of the disease. The ongoing study is testing one of the ingredients in Amylyx’s approved drug, Relyvrio, on its own. Positive results could bode well for Amylyx’s own pivotal study, which is expected to report later this year. However, if the results are overly positive, it may persuade patients and physicians to opt for the single ingredient, which is cheaper and more widely available, rather than choosing Relyvrio. Conversely, if the study fails, it could eliminate a near-term threat to Amylyx’s market share but would be seen as a negative for the company’s future trial.
We also see that the biotech industry is heavily influenced by macroeconomic factors. Despite mergers, clinical successes, and FDA approvals, market movements are still primarily driven by macroeconomic news. The XBI biotech index fell more than 5% on the news that inflation isn’t declining at the predicted rate. This decline signals that potential interest rate cuts by the Fed may not happen as quickly as expected. This, in turn, impacts the attractiveness of risky asset classes like biotech stocks in the eyes of the market.
Another piece of news from the biotech industry is the struggles of Aurinia Pharmaceuticals. The company saw its stock fall by 20% after disclosing that its strategic review did not lead to any successful partnerships or acquisitions. Despite engaging with over 60 potential partners or acquirers, Aurinia was unable to secure any deals, leading to a lack of confidence in the market. Due to this, the company has announced staff cuts and a discontinuation of development in two pipeline drugs, focusing solely on the commercialization of Lupkynis, its approved treatment.
On a more positive note, there is a sign of recovery for pharmaceutical contractors. IQVIA, a significant services provider to the drug industry, reported strong financial results, beating Wall Street’s estimates. Its share price rose 5% with an increase in demand for contract research services. This increase in demand could be a leading indicator of better days ahead for pharmaceutical contractors.
In other news, the National Institutes of Health has increased funding for long Covid research, signaling a growing focus on understanding the long-term effects of the disease. There are also reports of WuXi AppTec and WuXi Bio experiencing a slump as U.S. lawmakers seek a formal probe.
These updates highlight the intricacies of the biotech industry, where scientific advancements, market forces, and economic factors intersect. As biotech enthusiasts, staying informed about these developments is essential to understanding the broader landscape and potential opportunities in the industry.
If you’re interested in receiving more biotech updates and news, consider signing up for our biotech newsletter to stay informed about the latest trends, breakthroughs, and market movements. We hope this comprehensive update has provided valuable insights into the complexities of the biotech world and its relevance in today’s society.
